Literature DB >> 3709650

Effects of probenecid on enprofylline kinetics in man.

O Borgå, R Larsson, E Lunell.   

Abstract

Enprofylline 1 mg/kg, a new potent antiasthmatic xanthine derivative, which is mainly eliminated by renal excretion, was given intravenously to 6 normal subjects with and without oral pretreatment with 1 g probenecid. The latter caused a drop in the average total body clearance of enprofylline from 21 to 9.8 l/h, and in the average renal clearance from 17 to 8.0 l/h. The average half-life increased from 1.8 to 3.0 h. The volumes of distribution, Vz and Vss, both fell by about 25%, indicating that probenecid had restricted the distribution of enprofylline in the body. The plasma protein binding of enprofylline was not altered by probenecid. The results confirm the opinion that active tubular secretion accounts for a large proportion of the total elimination of enprofylline.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709650     DOI: 10.1007/bf00614308

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Renal clearance of theophylline in man.

Authors:  G Levy; R Koysooko
Journal:  J Clin Pharmacol       Date:  1976-07       Impact factor: 3.126

2.  Modification of penicillin distribution and elimination by probenecid.

Authors:  M Gibaldi; D Davidson; M E Plaut; M A Schwartz
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1970-05

3.  Renal elimination of cefoxitin and effect of probenecid after single and repeated doses.

Authors:  A Arvidsson; O Borgå; L Kager; R Pieper
Journal:  J Antimicrob Chemother       Date:  1981-04       Impact factor: 5.790

4.  Enprofylline, a principally new antiasthmatic xanthine.

Authors:  C G Persson; G Kjellin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1981-10

5.  Protein binding of enprofylline.

Authors:  K Tegnér; O Borgå; I Svensson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Enprofylline kinetics in healthy subjects after single doses.

Authors:  O Borgå; K E Andersson; L E Edholm; P O Fagerström; E Lunell; C G Persson
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

8.  Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease.

Authors:  E Lunell; N Svedmyr; K E Andersson; C G Persson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Tracheal relaxant and cardiostimulant actions of xanthines can be differentiated from diuretic and CNS-stimulant effects. Role of adenosine antagonism?

Authors:  C G Persson; I Erjefält; L E Edholm; J A Karlsson; C J Lamm
Journal:  Life Sci       Date:  1982-12-13       Impact factor: 5.037

10.  Furosemide kinetics and dynamics after kidney transplant.

Authors:  D E Smith; J G Gambertoglio; F Vincenti; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875

View more
  5 in total

Review 1.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

2.  The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease.

Authors:  J Kraan; J H Jonkman; G H Koëter; C H Gips; P E de Jong; T W van der Mark; I Ekman; R A de Zeeuw
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Enprofylline pharmacokinetics in children with asthma.

Authors:  C Hultqvist; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Enprofylline disposition in the presence and absence of amoxycillin or erythromycin.

Authors:  D S Sitar; F Y Aoki; D J Hoban; K G Hidinger; P R Montgomery; P A Mitenko
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

5.  Pharmacokinetics of enprofylline in healthy elderly subjects.

Authors:  E Lunell; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.